M. Ingham

413 total citations
33 papers, 333 citations indexed

About

M. Ingham is a scholar working on Psychiatry and Mental health, Economics and Econometrics and Rheumatology. According to data from OpenAlex, M. Ingham has authored 33 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Psychiatry and Mental health, 6 papers in Economics and Econometrics and 5 papers in Rheumatology. Recurrent topics in M. Ingham's work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Rheumatoid Arthritis Research and Therapies (5 papers) and Attention Deficit Hyperactivity Disorder (4 papers). M. Ingham is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (5 papers), Rheumatoid Arthritis Research and Therapies (5 papers) and Attention Deficit Hyperactivity Disorder (4 papers). M. Ingham collaborates with scholars based in United States, Belgium and United Kingdom. M. Ingham's co-authors include Keith Karcher, Akbar Ali Khan, Nicholas A Keks, Rachel Fournier, Trevor van Mierlo, Penny S. Albright, Jacques Le Lorier, David L. Keegan, S. Bolge and Lieven Annemans and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and The British Journal of Psychiatry.

In The Last Decade

M. Ingham

29 papers receiving 309 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Ingham United States	9	156	61	58	52	52	33	333
A. Reusch Germany	13	40 0.3×	14 0.2×	41 0.7×	36 0.7×	3 0.1×	34	295
Deborah Gamsu United Kingdom	9	18 0.1×	28 0.5×	19 0.3×	64 1.2×	8 0.2×	11	387
Rebecca Marshall United Kingdom	10	78 0.5×	8 0.1×	23 0.4×	44 0.8×	3 0.1×	21	282
Brian G. Ortmeier United States	12	143 0.9×	35 0.6×	17 0.3×	64 1.2×	1 0.0×	17	397
Jacob Harbo Andersen Denmark	9	62 0.4×	35 0.6×	14 0.2×	17 0.3×	4 0.1×	16	280
Gianluigi Casadei Italy	10	39 0.3×	75 1.2×	25 0.4×	47 0.9×	2 0.0×	17	377
Sandra Gavart United States	8	121 0.8×	26 0.4×	18 0.3×	154 3.0×	32 0.6×	16	370
Jennifer C. Samp United States	11	68 0.4×	29 0.5×	46 0.8×	62 1.2×	14 0.3×	28	320
Roben Das Gupta United Kingdom	7	196 1.3×	13 0.2×	10 0.2×	43 0.8×	6 0.1×	8	328
Anindya Banerjee India	11	50 0.3×	17 0.3×	15 0.3×	41 0.8×	4 0.1×	28	304

Countries citing papers authored by M. Ingham

Since Specialization

Citations

This map shows the geographic impact of M. Ingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Ingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Ingham more than expected).

Fields of papers citing papers by M. Ingham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Ingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Ingham. The network helps show where M. Ingham may publish in the future.

Co-authorship network of co-authors of M. Ingham

This figure shows the co-authorship network connecting the top 25 collaborators of M. Ingham. A scholar is included among the top collaborators of M. Ingham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Ingham. M. Ingham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ingham, M., et al.. (2024). Non-Medical Switching or Discontinuation Patterns among Patients with Non-Valvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States: A Claims-Based Analysis. SHILAP Revista de lepidopterología. 12(3). 252–263.

Tan, Hiangkiat, et al.. (2019). Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA. BMJ Open Diabetes Research & Care. 7(1). e000704–e000704. 6 indexed citations

Xie, Lin, et al.. (2017). Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers. Advances in Therapy. 34(6). 1398–1410. 9 indexed citations

Bolge, S., et al.. (2017). Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis. Patient Preference and Adherence. Volume 11. 661–669. 29 indexed citations

White, Marie, Aaron Yarlas, M. Ingham, & Chenglong Han. (2016). COGNITIVE DEBRIEFING OF THE SF-36V2 WITH MODERATE-TO-SEVERE CROHN’S DISEASE PATIENTS. Value in Health. 19(3). A316–A316. 2 indexed citations

Mierlo, Trevor van, Rachel Fournier, & M. Ingham. (2015). Targeting Medication Non-Adherence Behavior in Selected Autoimmune Diseases: A Systematic Approach to Digital Health Program Development. PLoS ONE. 10(6). e0129364–e0129364. 37 indexed citations

Tkacz, Joseph, et al.. (2015). Novel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid Arthritis.. PubMed. 8(9). 494–505. 4 indexed citations

Goren, Amir, et al.. (2014). Validation Of The Compliance-Questionnaire-Rheumatology, A Behavior-Focused Predictive Adherence Questionnaire, With The Morisky Medication Adherence Scale. Value in Health. 17(3). A50–A50. 3 indexed citations

Lofland, Jennifer H., et al.. (2014). Health care costs by level of adherence for infliximab patients with crohn’s disease. Value in Health. 17(3). A39–A39. 1 indexed citations

10.

Ingham, M., Vahram Ghushchyan, George Reed, et al.. (2012). PMS21 Mapping Health Care Costs to Clinical Disease Activity Where Cost Data is Lacking – A Novel Approach Using Medical Expenditure Panel Survey Data with the Corrona Rheumatoid Arthritis Disease Registry. Value in Health. 15(4). A37–A37. 1 indexed citations

11.

Ingham, M., Lorie Ellis, & S. Bolge. (2012). PMS12 Number Needed to Treat (NNT), Cost Per Responder (CPR) and Budget Impact (BI) of TNF Inhibitors (TNFi) in the Treatment of Psoriatic Arthritis (PSA). Value in Health. 15(4). A35–A35. 1 indexed citations

12.

Bolge, S., et al.. (2012). Comparative Multidatabase Analysis of Dosing Patterns and Infusion Intervals for the First 12 Infliximab Infusions in Patients With Rheumatoid Arthritis. Clinical Therapeutics. 34(12). 2286–2292. 6 indexed citations

13.

Bolge, S., et al.. (2012). AB1386 Rheumatologists play a key role in shared decision-making with patients in the choice to initiate biologic therapy for treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases. 71. 717–717. 1 indexed citations

14.

Buysman, Erin, et al.. (2011). PSY68 DEFINITIONS OF ANTI-TNF DISCONTINUATION MAY IMPACT UNDERSTANDING OF REAL-WORLD UTILIZATION PATTERNS. Value in Health. 14(3). A71–A71. 1 indexed citations

15.

Merchant, Sanjay, Chris Gast, Dilip Nathwani, et al.. (2008). Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clinical Therapeutics. 30(4). 717–733. 34 indexed citations

16.

Keks, Nicholas A, M. Ingham, Akbar Ali Khan, & Keith Karcher. (2007). Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. The British Journal of Psychiatry. 191(2). 131–139. 75 indexed citations

17.

Caleo, Sue, et al.. (2005). PMH59 THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY—E-STAR: BASELINE RESULTS FOR GERMANY, SPAIN AND AUSTRALIA. Value in Health. 8(3). 403–403. 1 indexed citations

18.

Farmer, Didi Bertrand, et al.. (2004). PMH7 THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY—E-STAR: AN ELECTRONIC REGISTRY TO EVALUATE OUTCOMES DATA IN PATIENTS WITH SCHIZOPHRENIA/SCHIZOAFFECTIVE DISORDER. Value in Health. 7(6). 778–778. 1 indexed citations

19.

Annemans, Lieven, et al.. (2003). A cost analysis of the management of attention-deficit/hyperactivity disorder (ADHD) in children in the UK. Journal of Medical Economics. 6(1-4). 79–94. 7 indexed citations

20.

Annemans, Lieven & M. Ingham. (2002). Estimating cost-effectiveness of concerta oros in attention-deficit/hyperactivity disorder (ADHD) - Adapting the Canadian coordinating office for health technology assessment's (CCOHTA) economic model of methylphenidate immediate release versus behavioural interventions from a parent's perspective. Poster presentation at the ISPOR 5th annual European Conference. Rotterdam 3-5/11/2002.. Value in Health. 5(6). 517–517. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact